Camp4 Therapeutics (CAMP) director awarded 56,000 stock options at $4.46 strike

Rhea-AI Filing Summary

Camp4 Therapeutics director Michael F. MacLean received a new stock option award for 56,000 shares of common stock. The option has an exercise price of $4.46 per share and expires on March 31, 2036. This is a compensation-related grant, not an open-market purchase.

The option covers 56,000 underlying shares and was awarded at no cost on the grant date. The shares underlying the option vest in equal monthly installments over three years starting from the grant date, so MacLean earns the right to exercise portions of the award gradually over time.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MacLean Michael F

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	56,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 56,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 56,000 options Exercise price: $4.46 per share Underlying shares: 56,000 shares +3 more

6 metrics

Options granted 56,000 options Stock Option (Right to Buy) grant on April 1, 2026

Exercise price $4.46 per share Conversion or exercise price for granted options

Underlying shares 56,000 shares Common stock underlying the option grant

Expiration date March 31, 2036 Option expiration for this grant

Post-grant derivative holdings 56,000 options Total derivative securities following transaction

Vesting period 3 years, monthly Equal monthly vesting from grant date over three years

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vest in equal monthly installments

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 4.4600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-03-31T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest in equal monthly installments financial

"vest in equal monthly installments over a period of three years"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MacLean Michael F

(Last) (First) (Middle)

C/O CAMP4 THERAPEUTICS CORPORATION

ONE KENDALL SQ., BLDG 1400 WEST, 3RD FL.

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.46	04/01/2026		A		56,000		(1)	03/31/2036	Common Stock	56,000	$0	56,000	D

Explanation of Responses:

1. The shares underlying the option vest in equal monthly installments over a period of three years commencing from the date of grant.

Remarks:

	/s/ Josh Mandel-Brehm, as Attorney-in-Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Camp4 Therapeutics (CAMP) report for Michael F. MacLean?

Camp4 Therapeutics reported that director Michael F. MacLean received a grant of stock options for 56,000 shares. The award is a compensation-related acquisition, not an open-market buy, giving him the right to purchase common stock at a fixed exercise price over time.

How many Camp4 Therapeutics (CAMP) shares are covered by Michael MacLean’s new options?

Michael MacLean’s new stock option award covers 56,000 shares of Camp4 Therapeutics common stock. These options give him the right to buy that number of shares at a preset exercise price once the underlying portions vest over the three-year schedule.

What is the exercise price and expiration date of Michael MacLean’s Camp4 stock options?

The stock options granted to Michael MacLean have an exercise price of $4.46 per share and expire on March 31, 2036. This means he may buy Camp4 common shares at $4.46, once vested, any time before that expiration date, subject to plan terms.

How do Michael MacLean’s Camp4 (CAMP) stock options vest over time?

The options granted to Michael MacLean vest in equal monthly installments over three years starting from the grant date. Each month, a portion of the 56,000 underlying shares becomes exercisable, aligning his compensation with continued service over the full three-year period.

Is Michael MacLean’s Camp4 (CAMP) Form 4 transaction an open-market stock purchase?

No, Michael MacLean’s reported transaction is a grant of stock options as compensation, coded as an award acquisition. He did not buy shares in the open market; instead, he received the right to purchase stock later at a fixed $4.46 exercise price.